Evaluation of the Counter-Regulatory Response to Hypoglycaemia Following LY2605541 Administration Compared to Insulin Glargine in Patients With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Insulin peglispro (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 03 Dec 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.